Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant huma...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2021-12-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/2782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839575284687306752 |
|---|---|
| author | Julia G. Levina Nato D. Vashakmadze Leyla S. Namazova-Baranova Elena A. Vishneva Natalia V. Zhurkova Kamilla E. Efendieva Anna A. Alekseeva Vera G. Kalugina |
| author_facet | Julia G. Levina Nato D. Vashakmadze Leyla S. Namazova-Baranova Elena A. Vishneva Natalia V. Zhurkova Kamilla E. Efendieva Anna A. Alekseeva Vera G. Kalugina |
| author_sort | Julia G. Levina |
| collection | DOAJ |
| description | Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant human I2S. The major issue of ERT is development of allergic (sometimes up to severe anaphylaxis) reactions to recombinant enzymes. The article covers features of infusion-related reactions to ERT, it describes pathogenesis, diagnostic criteria management algorithm of anaphylaxis. Whereas, there is the need of further studies on allergic infusion-related reactions to ERT in children. |
| format | Article |
| id | doaj-art-43b99bf093e444f8a3b9a08a8d576030 |
| institution | Matheson Library |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-43b99bf093e444f8a3b9a08a8d5760302025-08-04T13:09:41Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352021-12-01206s62462910.15690/vsp.v20i6S.23721998Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type IIJulia G. Levina0Nato D. Vashakmadze1Leyla S. Namazova-Baranova2Elena A. Vishneva3Natalia V. Zhurkova4Kamilla E. Efendieva5Anna A. Alekseeva6Vera G. Kalugina7Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod State National Research UniversityResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Medical Genetic Research Center named after N.P. BochkovResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant human I2S. The major issue of ERT is development of allergic (sometimes up to severe anaphylaxis) reactions to recombinant enzymes. The article covers features of infusion-related reactions to ERT, it describes pathogenesis, diagnostic criteria management algorithm of anaphylaxis. Whereas, there is the need of further studies on allergic infusion-related reactions to ERT in children.https://vsp.spr-journal.ru/jour/article/view/2782mucopolysaccharidosis type iienzyme replacement therapyidursulfaseidursulfase betainfusion-related reactionsanaphylaxis |
| spellingShingle | Julia G. Levina Nato D. Vashakmadze Leyla S. Namazova-Baranova Elena A. Vishneva Natalia V. Zhurkova Kamilla E. Efendieva Anna A. Alekseeva Vera G. Kalugina Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II Вопросы современной педиатрии mucopolysaccharidosis type ii enzyme replacement therapy idursulfase idursulfase beta infusion-related reactions anaphylaxis |
| title | Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II |
| title_full | Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II |
| title_fullStr | Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II |
| title_full_unstemmed | Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II |
| title_short | Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II |
| title_sort | allergic reactions at enzyme replacement therapy in children with mucopolysaccharidosis type ii |
| topic | mucopolysaccharidosis type ii enzyme replacement therapy idursulfase idursulfase beta infusion-related reactions anaphylaxis |
| url | https://vsp.spr-journal.ru/jour/article/view/2782 |
| work_keys_str_mv | AT juliaglevina allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT natodvashakmadze allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT leylasnamazovabaranova allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT elenaavishneva allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT nataliavzhurkova allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT kamillaeefendieva allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT annaaalekseeva allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii AT veragkalugina allergicreactionsatenzymereplacementtherapyinchildrenwithmucopolysaccharidosistypeii |